ArcticZymes Technologies (AZT.OL) Stock Analysis & AI Equity Report
ArcticZymes Technologies (AZT.OL) overview
ArcticZymes Technologies (AZT.OL) stock analysis and AI equity research. For the latest completed financial year, 2025, ArcticZymes Technologies reported revenue of NOK 113m and operating profit of NOK 2.8m; the year-end share price was 20.60 NOK and market capitalisation was NOK 1,071m. ArcticZymes Technologies is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ArcticZymes Technologies's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About ArcticZymes Technologies
ArcticZymes Technologies ASA develops, manufactures, and sells specialized recombinant enzymes for life science applications. Its products are used in molecular research and diagnostics, as well as in biomanufacturing for gene therapy and vaccine production. The company’s portfolio includes salt-active nucleases, other nucleases, polymerases, and related kits for demanding laboratory and manufacturing conditions.
Generate the ArcticZymes Technologies report
ArcticZymes Technologies is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ArcticZymes Technologies and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on ArcticZymes Technologies
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.